Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study
Introduction The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) may be as high as 38% in the adult population with potential serious complications, multiple comorbidities and a high socioeconomic burden. However, there is a general lack of awareness and knowledge abou...
Saved in:
| Main Authors: | Manuel Castro Cabezas, Joanne Verheij, Diederick E Grobbee, Marco Alings, Amalia Gastaldelli, Oscar H Franco, Vlad Ratziu, Helena Cortez-Pinto, Christophe Moreno, Jörn M Schattenberg, Jean W M Muris, Michail Doukas, Sven Francque, Luca Miele, Manuel Romero-Gómez, Lawrence Serfaty, José Willemse, Maarten E Tushuizen, Thomas Hankemeier, Céline Fournier-Poizat, Vivian D de Jong, Radan Bruha, George V Dedoussis, Adriaan G Holleboom, D Cristina Stefan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/5/e092731.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Resmetirom: The First Disease-Specific Treatment for MASH
by: Ali Mohamed Mousa, et al.
Published: (2025-01-01) -
Pharmacotherapeutic perspectives on nutraceuticals in the treatment of MASLD and MASH
by: Ali H. Eid, et al.
Published: (2025-05-01) -
Validation of the diagnostic accuracy of the acFibroMASH index for at-risk MASH in patients with metabolic dysfunction-associated steatotic liver disease
by: Yunfei Wu, et al.
Published: (2025-03-01) -
Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort.
by: Willy Theel, et al.
Published: (2025-01-01) -
Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort
by: Willy Theel, et al.
Published: (2025-01-01)